CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 2 enrolled
Drug / intervention
ranibizumabdrug
Likely dose
ranibizumab 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00561834
NCT00561834Phase 1Completed
CompareCT.gov

Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy (NAION)

University of Colorado, Denver·interventional·Posted Nov 21, 2007·Updated Sep 30, 2016

In Brief

A Phase 1 clinical trial evaluating ranibizumab for Nonarteritic Anterior Ischemic Optic Neuropathy. Completed, enrolled 2 participants across 1 site.

Detailed Summary

The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonarteritic Anterior Ischemic Optic Neuropathy
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 21, 2007
Enrollment StartNov 1, 2007
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.6 years ago

Interventions

ranibizumabdrug

All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.